DiaMedica Therapeutics Inc (DMAC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DiaMedica Therapeutics Inc (DMAC) has a cash flow conversion efficiency ratio of -0.138x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.76 Million) by net assets ($56.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DiaMedica Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how DiaMedica Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read DiaMedica Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
DiaMedica Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DiaMedica Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Coremax Corp
TW:4739
|
-0.027x |
|
Benchmark Metals Inc
V:CEI
|
0.029x |
|
Forrestania Resources Ltd
AU:FRS
|
-0.010x |
|
Yuen Foong Yu Consumer Prod
TW:6790
|
0.071x |
|
Sichuan Langsha Holding Ltd
SHG:600137
|
-0.016x |
|
Grupo Traxión S.A.B. de C.V
MX:TRAXIONA
|
0.047x |
|
ANGLO ASIAN MINING
F:A4A
|
N/A |
|
Rapid7 Inc
NASDAQ:RPD
|
0.243x |
Annual Cash Flow Conversion Efficiency for DiaMedica Therapeutics Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of DiaMedica Therapeutics Inc from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see DiaMedica Therapeutics Inc (DMAC) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $56.11 Million | $-29.06 Million | -0.518x | +4.47% |
| 2024-12-31 | $40.72 Million | $-22.08 Million | -0.542x | -47.81% |
| 2023-12-31 | $51.06 Million | $-18.73 Million | -0.367x | -1.42% |
| 2022-12-31 | $31.83 Million | $-11.51 Million | -0.362x | -29.96% |
| 2021-12-31 | $44.02 Million | $-12.25 Million | -0.278x | +21.18% |
| 2020-12-31 | $26.01 Million | $-9.19 Million | -0.353x | +70.45% |
| 2019-12-31 | $7.62 Million | $-9.10 Million | -1.195x | -257.17% |
| 2018-12-31 | $17.02 Million | $-5.70 Million | -0.335x | +93.15% |
| 2017-12-31 | $799.00K | $-3.90 Million | -4.881x | -101.17% |
| 2016-12-31 | $1.25 Million | $-3.02 Million | -2.426x | -318.40% |
| 2015-12-31 | $-1.23 Million | $-1.37 Million | 1.111x | -54.77% |
| 2014-12-31 | $-1.53 Million | $-3.76 Million | 2.456x | +161.68% |
| 2013-12-31 | $1.38 Million | $-5.50 Million | -3.983x | -64.48% |
| 2012-12-31 | $2.26 Million | $-5.48 Million | -2.421x | -320.16% |
| 2011-12-31 | $5.96 Million | $-3.44 Million | -0.576x | -106.67% |
| 2010-12-31 | $8.52 Million | $-2.38 Million | -0.279x | +86.39% |
| 2009-12-31 | $1.05 Million | $-2.15 Million | -2.049x | -288.44% |
| 2008-12-31 | $2.78 Million | $-1.47 Million | -0.528x | -76.73% |
| 2007-12-31 | $4.06 Million | $-1.21 Million | -0.299x | +75.65% |
| 2006-12-31 | $653.60K | $-801.16K | -1.226x | +25.36% |
| 2005-12-31 | $506.11K | $-831.17K | -1.642x | -1852.50% |
| 2004-12-31 | $-1.06 Million | $-99.35K | 0.094x | -- |
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal… Read more